Abstract:AbstractFrontotemporal lobar degeneration (FTLD) has been associated with toxic intracellular aggregates of hyperphosphorylated tau (FTLD‐tau). Moreover, genetic studies identified mutations in the MAPT gene encoding tau in familial cases of the disease. In this review, we cover a range of aspects of tau function, both in the healthy and diseased brain, discussing several in vitro and in vivo models. Tau structure and function in the healthy brain is presented, accentuating its distinct compartmentalization in neurons and its role in microtubule stabilization and axonal transport. Furthermore, tau‐driven pathology is discussed, introducing current concepts and the underlying experimental evidence. Different aspects of pathological tau phosphorylation, the protein's genomic and domain organization as well as its spreading in disease, together with MAPT‐associated mutations and their respective models are presented. Dysfunction related to other post‐transcriptional modifications and their effect on normal neuronal functions such as cell cycle, epigenetics and synapse dynamics are also discussed, providing a mechanistic explanation for the observations made in FTLD‐tau cases, with the possibility for therapeutic intervention. image In this review, we cover aspects of tau function, both in the healthy and diseased brain, referring to different in vitro and in vivo models. In healthy neurons, tau is compartmentalized, with higher concentrations found in the distal part of the axon. Cargo molecules are sensitive to this gradient. A disturbed tau distribution, as found in frontotemporal lobar degeneration (FTLD‐tau), has severe consequences for cellular physiology: tau accumulates in the neuronal soma and dendrites, leading among others to microtubule depolymerization and impaired axonal transport. Tau forms insoluble aggregates that sequester additional molecules stalling cellular physiology. Neuronal communication is gradually lost as toxic tau accumulates in dendritic spines with subsequent degeneration of synapses and synaptic loss. Thus, by providing a mechanistic explanation for the observations made in FTLD‐tau cases, arises a possibility for therapeutic interventions.This article is part of the Frontotemporal Dementia special issue.

Tau in Health and Neurodegenerative Diseases

Tau in neurodegenerative disease

Tau in neurodegenerative diseases: molecular mechanisms, biomarkers, and therapeutic strategies

Tau in Alzheimer's Disease: Mechanisms and Therapeutic Strategies.

Tau Toxicity in Neurodegeneration

Defects in the autophagy lysosomal pathway in a cell model of disease‐associated tau

Tau in physiology and pathology

Tau protein structure and dynamics

Role of Tau Protein in Neurodegenerative Diseases and Development of Its Targeted Drugs: A Literature Review

Tauopathies: new perspectives and challenges

Cellular and pathological functions of tau

Tauopathies: Mechanisms and Therapeutic Strategies

Post-Translational Modifications in Tau and Their Roles in Alzheimer's Pathology

Tau Protein Interaction Partners and Their Roles in Alzheimer’s Disease and Other Tauopathies

Tau Protein: Relevance to Parkinson'S Disease

Tau Protein and Tauopathies: Exploring Tau Protein‐Protein and Microtubule Interactions, Cross‐Interactions and Therapeutic Strategies.

Tau Abnormalities and the Potential Therapy in Alzheimer’s Disease

Posttranslational Modifications of Tau - Role in Human Tauopathies and Modeling in Transgenic Animals

Tau-mediated Neurodegeneration and Potential Implications in Diagnosis and Treatment of Alzheimer's Disease

Microtubule-associated protein tau as a therapeutic target in neurodegenerative disease

Tau physiology and pathomechanisms in frontotemporal lobar degeneration